XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information (Tables)
 3 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Long-lived Assets by Geographic Areas
The following table presents the Company’s long-lived assets for its most significant geographic markets (in thousands):
 September 30, 2025June 30, 2025
United States$14,143 $18,446 
Foreign:
Japan1,716 1,901 
Other foreign markets427 472 
Total foreign markets2,143 2,373 
Total long-lived assets$16,286 $20,819 
Schedule of Revenue Disaggregated by Geographic Regions The following table presents the Company’s revenue disaggregated by these markets (in thousands):
 Three Months Ended September 30,
 20252024
United States$35,216 $35,268 
Foreign:
Japan6,192 5,983 
Other foreign markets6,153 5,963 
Total foreign markets12,345 11,946 
Total revenue, net$47,561 $47,214 
Schedule of Segment Reporting Information, by Segment
The following table presents the Company’s segment revenue and expenses and segment net income for the three months ended September 30, 2025 and 2024 (in thousands):

 Three Months Ended September 30,
 20252024
Revenue, net$47,561 $47,214 
Cost of sales(9,745)(9,491)
Consultant commissions(19,385)(19,093)
Consultant incentives, promotions, and recognition(1,310)(1,212)
Labor and benefits(6,836)(7,117)
Stock compensation(826)(917)
Events(531)(189)
Depreciation and amortization(610)(797)
Credit card and bank processing fees(1,337)(1,409)
Other segment items(1)
(4,827)(4,470)
Interest income97 67 
Interest expense(10)(8)
Income tax expense(86)(752)
Net income$2,155 $1,826 
(1) Other general and administrative expenses include legal, professional services, rent, utilities, and other miscellaneous expenses.
Disaggregation of Revenue The following table shows revenue by product line for the three months ended September 30, 2025 and 2024 (in thousands):
Three Months Ended September 30,
20252024
Protandim® product line
$22,057 $24,198 
TrueScience® product line
9,867 12,792 
LifeVantage® product line
9,105 3,902 
AXIO® product line
3,458 3,532 
PhysIQ™ product line
1,236 1,144 
Petandim® product line
477 534 
Other(1)
1,361 1,112 
Total revenue, net$47,561 $47,214 
(1) Other revenue includes shipping and handling revenue, event related revenue, and other revenues impracticable to allocate to a specific product line.